ReviewDiabetes, metabolic syndrome and obesity : targets and therapy2026
Recent Updates on the Role of Genetic and Epigenetic Factors in the Pathogenesis of the Metabolic Syndrome.
Review in Diabetes, metabolic syndrome and obesity : targets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metabolic syndrome (MetS) is a multifactorial disorder characterized by obesity, hypertension, dyslipidemia, and diabetes, all of which contribute to the global burden of cardiovascular diseases. Growing evidence highlights the interplay between genetic predisposition and epigenetic modifications in shaping susceptibility to MetS and its complications. Scope of Review: This systematic review analyzed 55 relevant studies published in the last decade, exploring genetic polymorphisms, DNA methylation, and non-coding RNAs (ncRNAs) associated with MetS. Result and Conclusion: Our findings reveal that MetS arises from the convergence of inherited genomic risk and environmentally driven epigenetic reprogramming in the forms of DNA methylation changes and ncRNAs involvement, which affect important genes related to crucial biological functions such as neuroendocrine, adipogenesis and insulin signaling, glucose and lipid metabolism, and immune response and inflammatory signaling. Understanding these interactions may facilitate the development of predictive biomarkers and targeted interventions to mitigate cardiometabolic risks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.